Shopping Cart
- Remove All
Your shopping cart is currently empty
Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) is an antibody-activated molecule coupling (ADC) with anticancer and antitumour activity.Trastuzumab deruxtecan has been shown to have an ameliorative effect in HER2-positive breast and gastric cancers.
Catalog No. T36646Cas No. 1826843-81-5
Select Batch
Concentration:9.37 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Trastuzumab deruxtecan
Catalog No. T36646Cas No. 1826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-activated molecule coupling (ADC) with anticancer and antitumour activity.Trastuzumab deruxtecan has been shown to have an ameliorative effect in HER2-positive breast and gastric cancers.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $728 | In Stock | |
| 5 mg | $1,480 | In Stock | |
| 10 mg | $1,960 | In Stock | |
| 25 mg | $2,980 | In Stock | |
| 50 mg | $3,930 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Trastuzumab deruxtecan"
N3-PEG4-C2-NHS ester
T16259944251-24-5
N3-PEG4-C2-NHS ester is a noncleavable, four-unit polyethylene glycol (PEG) linker essential for the synthesis of antibody-drug conjugates (ADCs).
- $35
Size
QTY
Brentuximab vedotin
T76707914088-09-8
Brentuximab vedotin (SGN-35) is an antibody-activated molecule coupling (ADC) targeting CD30 with antitumor activity for the study of lymphomas.
- $413
Size
QTY
Glembatumumab vedotin
T741781182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
- $718
Size
QTY
Disitamab vedotin
T395952136633-23-1
Disitamab vedotin (RC-48) is an antibo-active molecular conjugate (ADC) containing a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) that binds to the cytotoxic agent MMAE via a degradable linker. Disitamab vedotin showed anti-tumor and anti-proliferation activities in gastric cancer cells with different HER-2 expression levels, and inhibited the expression of HER-2 protein in gastric cancer cells.
- $347
Size
QTY
Enfortumab vedotin-ejfv
T780651346452-25-2
Enfortumab vedotin-ejfv is an antibody-drug conjugate targeting Nectin-4, employed in the treatment of urothelial carcinoma [1].
- $835
Size
QTY
Polatuzumab vedotin
T778231313206-42-6
Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1].
- $1,620
Size
QTY
Trastuzumab emtansine
T366471018448-65-1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2].
- $1,320
Size
QTY
Sacituzumab govitecan
T778241491917-83-9
Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity [1].
- Inquiry Price
Size
QTY
Gemtuzumab ozogamicin
T78047220578-59-6
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a CD33-specific monoclonal antibody linked to a cytotoxic agent derived from Calicheamicin, utilized in the investigation of acute myeloid leukemia [1].
- Inquiry Price
Size
QTY
Labetuzumab govitecan
T255931469876-18-3
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
- Inquiry Price
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Trastuzumab deruxtecan (T-DXd) is an antibody-activated molecule coupling (ADC) with anticancer and antitumour activity.Trastuzumab deruxtecan has been shown to have an ameliorative effect in HER2-positive breast and gastric cancers. |
| Targets&IC50 | Axl(KPL-4 cells):109.7 pM |
| In vitro | Trastuzumab deruxtecan, at concentrations ranging from 1 pM to 10 nM for 5 days (solution), inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM[4].Trastuzumab deruxtecan, at 10 nM for 5 days (solution), shows bystander killing effects in HER2-negative MDA-MB-468 cells[4]. |
| In vivo | Trastuzumab deruxtecan (solution) at a single intravenous dose of 3 mg/kg exhibits antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition[4].Trastuzumab deruxtecan (solution) administered intravenously on days 0 and 7 at a dose of 10 mg/kg inhibits tumor growth in the EMT6-hHER2 syngeneic mouse model[3].Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells[4] |
| Alias | DS-8201a, VRN-101099, DS 8201, T-DXd |
| Molecular Weight | Approximately 45.42 kDa |
| Cas No. | 1826843-81-5 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Trastuzumab deruxtecan | purchase Trastuzumab deruxtecan | Trastuzumab deruxtecan cost | order Trastuzumab deruxtecan | Trastuzumab deruxtecan chemical structure | Trastuzumab deruxtecan in vivo | Trastuzumab deruxtecan in vitro | Trastuzumab deruxtecan molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.